PSMA-PET: Deep Radiomic Biomarkers of Progression and Response Prediction in Prostate Cancer
Launched by CENTRE HOSPITALIER DE L'UNIVERSITÉ DE MONTRÉAL (CHUM) · Jul 19, 2018
Trial Information
Current as of August 20, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is exploring a new imaging technique called PSMA-PET to improve the detection and monitoring of prostate cancer. Prostate cancer is a common type of cancer in men, and accurately understanding its spread is crucial for determining the best treatment. The study aims to use PSMA-PET scans, which are more sensitive in finding cancer spread compared to standard imaging methods, along with advanced computer learning techniques to identify patterns that could help predict how patients respond to treatment.
Men aged 65 to 74 with prostate cancer who are being treated at a specific hospital (CHUM) and whose doctors have recommended a PSMA-PET scan may be eligible to participate. Participants will undergo PSMA-PET scans and their results will be analyzed to find new ways to predict the progression of the disease and response to therapy. It’s important to note that individuals who have claustrophobia or cannot complete the imaging procedure will not be able to join the study. This trial could lead to better ways of managing prostate cancer in the future.
Gender
MALE
Eligibility criteria
- Inclusion Criteria:
- • Patients with prostate cancer, being followed and treated at CHUM, whose treating physician at CHUM has requested a PSMA-PET scan.
- Exclusion Criteria:
- • Claustrophobia/inability to complete imaging procedure.
About Centre Hospitalier De L'université De Montréal (Chum)
The Centre Hospitalier de l'Université de Montréal (CHUM) is a leading academic health institution in Canada, dedicated to advancing patient care through innovative research and clinical excellence. As a prominent sponsor of clinical trials, CHUM is committed to leveraging its multidisciplinary expertise and state-of-the-art facilities to facilitate groundbreaking studies that enhance medical knowledge and improve health outcomes. Collaborating with a network of healthcare professionals and researchers, CHUM fosters a rigorous research environment that prioritizes patient safety, ethical standards, and scientific integrity, positioning itself at the forefront of medical advancements.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Montréal, Quebec, Canada
Patients applied
Trial Officials
Daniel Juneau, MD
Principal Investigator
Centre hospitalier de l'Université de Montréal (CHUM)
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials